In a key point in its growth strategy, Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is expanding its Oxford presence to the new Schrödinger Building on The Oxford Science Park, one of the UK’s leading parks for science and technology companies. In its new facilities, Exscientia is bringing together its computer scientists, drug designers and biologists all under one roof to allow it to rapidly expand its platform development and proprietary drug discovery portfolio. The move also allows the firm to expand its recruitment activities in Oxford. Exscientia is the third occupant of The Oxford Science Park’s new Schrödinger Building, and it expects to move in by the end of the year.
As of 30th June 2016, Frontier IP Group Plc (LON:FIPP) have a 5% holding in Exscientia.
Frontier IP Group (LON:FIPP)unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.